How Can You Use Newer Therapies to Improve Clinical Decision-Making and Long-Term Health Outcomes for Patients with Chronic Lymphocytic Leukemia Acute Myeloid Leukemia?
Authors: Welch Lauren , Allen Russie 
Published: December 2023

The Catalyst initiative, developed by Med Learning Group in 2019 with continued grant support year-on year, is a comprehensive continuing medical education platform that provides innovative methods to increase HCPs' competence surrounding essential aspects of CLL and AML management, with a specific focus on molecular testing, therapy selection, and the combination of established and emerging treatments. By equipping healthcare professionals with up-to-date knowledge and skills, the Catalyst initiative empowers them to make informed decisions that lead to improved patient outcomes.
The Catalyst website (www.Catalyst-HM.com) includes HCP- and patient-facing and serves as a validated platform for the latest guidelines and research on CLL and AML. There have been over 16500 views of the website since its launch in 2019. Learners also have access to a variety of accredited educational programs and tools, such as downloadable animations illustrating the value of molecular testing and how to use results to guide treatment choice and a Personalized Poster Portal where learners can choose a variety of images for a poster that is sent to their practice setting. In 2021/2022, these live and online programs have educated over 10000 HCPs
Learners have particularly appreciated the innovative nature of the CATALYST Initiative, with 98% indicating the VR animations included in a variety of programming improved their learning experience and knowledge retention (N=2997). At the last two ASH annual meetings, learners could participate in the CATALYST VR Room, a digital version of which can be viewed here: https://catalyst-hm.com/virtualbooth/. Please view footage and attitudinal feedback from learners here.
The proposed poster would review the gains in knowledge and competence among CATALYST learners longitudinally from 2019 - 2022, demonstrating the value of this community in helping to advance the translation of the latest science to practice behavior. As demonstrated in the figure below (Please see figure 1), in 2022 hematologists / oncologists increased their ability to apply treatment best practices in newly diagnosed and R/R AML by 28%, and their ability to individualize selection of therapies for treatment-naïve and R/R CLL based on disease- and patient-specific factors 31% (N=2953). While these are significant gains, baseline pre/posttest scores in the sixtieth percentile among specialists suggest these are important areas for continued focus.
The CATALYST program has also had a significant impact on learners' practice, based on 60- and 90-day follow-on assessments (n=113). 87% of respondents indicate they now actively use strategies and tools to address adverse events in the treatment of CLL or AML with all or most of their patients. Additionally, 79% indicated increased incorporation of patient and disease-specific factors when treating newly diagnosed or relapsed/refractory AML patients.
Over the last four years, the Catalyst initiative has helped the oncology/hematology multidisciplinary team increase their ability to utilize molecular and genetic features as well as patient characteristics to design individualized management plans to enhance patient outcomes. The proposed poster will describe CATALYST offerings and demonstrate its impact on HCPs' ability to translate the latest data and guidelines to practice for their patients with AML and CLL.